close read more

Medical affairs

A word from…

PHILIPPE GONNARD, Executive Vice President Global Medical & Patient Affairs

Our efforts to listen, advise and prevent is essential, both for the patients with whom we work each day and the doctors we support and with whom we share best practice.

Servier has chosen to target specialist diseases, involving increasingly complex mechanisms of action. In this regard, the Directorate of Global Medical Affairs has five key missions:

1. To encourage a balanced exchange of knowledge with the scientific and medical communities

Servier is building partnerships with learned societies to encourage the scientific exchange and advancement of medical knowledge.

Moreover, we provide information on our therapeutic solutions to the medical community at scientific conferences whilst ensuring that the medical information provided is both practical and high quality, with regard to existing professional codes.

2. To better understand medical practice and identify new therapeutic needs

We are putting in place real life clinical and observational studies to better understand patient care in numerous diseases as well as the practical application of our medicines.

3. To develop partnerships with patient associations

The desire of Servier to place the patient at the centre of our thinking is a major commitment. We seek to meet the expectations of the patient and consequently adapt the choice of new therapeutic solutions.

Our commitment can also be seen through the implementation of specific programmes to access our medicines which allow patients to benefit more quickly from innovation, particularly in oncology.

4. To respond to all questions raised by healthcare professionals or patients, in France and internationally

Through its Medical Information Department, Global Medical Affairs are also responsible for providing the best response to healthcare professionals (doctors, pharmacists, nurses, etc.), patients and caregivers, with regard to the correct use of medicines from our Laboratory.



Servier recognizes the importance of Investigator Initiated Trials (IITs) conducted by Third-Party Sponsors. For this purpose, Servier is committed to support medical and scientific research which contributes to better understand the Group’s therapeutic solutions as well as to explore new opportunities to address unmet patient medical needs.

Last news

Meeting the challenge of adherence: a Servier study presented at the ESH 2022 Annual Meeting!
Appointment of Angelo Paci, Oncology & Immuno-Oncology Program Leader
Patient associations’ perception of pharmaceutical companies: Servier is making progress!